Cassava Sciences, Inc. (SAVA)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Loading interactive chart…
- Zacks
Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $30.44, marking a -1.17% move from the previous day.
- Zacks
Cassava Sciences, Inc. (SAVA) Stock Moves -1.38%: What You Should Know
In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $26.43, marking a -1.38% move from the previous day.
- GlobeNewswire
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida
© 2022 Yahoo. All rights reserved.
